A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Artemisinin and artemisinin-based combination therapy (ACT) partner drug resistance in Plasmodium falciparum have spread across the Greater Mekong Subregion compromising antimalarial treatment. The current 3-day artemether-lumefantrine regimen has been associated with high treatment failure rates in pregnant women. Although ACTs are recommended for treating Plasmodium vivax malaria, no clinical trials in pregnancy have been reported. Methods: Pregnant women with uncomplicated malaria on the Thailand-Myanmar border participated in an open-label randomized controlled trial comparing dihydroartemisinin-piperaquine (DP), artesunate-mefloquine (ASMQ) and a 4-day artemether-lumefantrine regimen (AL + ). The primary endpoint for P. falciparum infections was the PCR-corrected cure rate and for P. vivax infections was recurrent parasitaemia, before delivery or day 63, whichever was longer, assessed by Kaplan-Meier estimate. Results: Between February 2010 and August 2016, 511 pregnant women with malaria (353 P. vivax , 142 P. falciparum , 15 co-infections, 1 Plasmodium malariae ) were randomized to either DP ( n =170), ASMQ ( n =169) or AL + ( n =172) treatments. Successful malaria elimination efforts in the region resulted in premature termination of the trial. The majority of women had recurrent malaria (mainly P. vivax relapses, which are not prevented by these treatments). Recurrence-free proportions (95% confidence interval [95% CI]) for vivax malaria were 20.6% (5.1–43.4) for DP ( n =125), 46.0% (30.9–60.0) for ASMQ ( n =117) and 28.7% (10.0–50.8) for AL + ( n =126). DP and ASMQ provided longer recurrence-free intervals. PCR-corrected cure rates (95% CI) for falciparum malaria were 93.7% (81.6–97.9) for DP ( n =49), 79.6% (66.1–88.1) for AMSQ ( n =55) and 87.5% (74.3–94.2) for AL + ( n =50). Overall 65% (85/130) of P. falciparum infections had Pfkelch13 propeller mutations which increased over time and recrudescence occurred almost exclusively in them; risk ratio 9.42 (95% CI 1.30–68.29). Among the women with falciparum malaria, 24.0% (95% CI 16.8–33.6) had P. vivax parasitaemia within 4 months. Nausea, vomiting, dizziness and sleep disturbance were more frequent with ASMQ. Miscarriage, small-for-gestational-age and preterm birth did not differ significantly among the treatment groups, including first trimester exposures ( n =46). Conclusions: DP was well tolerated and safe, and was the only drug providing satisfactory efficacy for P. falciparum -infected pregnant woman in this area of widespread artemisinin resistance. Vivax malaria recurrences are very common and warrant chloroquine prophylaxis after antimalarial treatment in this area. Trial registration: ClinicalTrials.gov identifier NCT01054248 , registered on 22 January 2010.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Cumulative proportions of treatment success over time for each arm stratified by malaria species estimated by Kaplan-Meier estimator. a Plasmodium falciparum PCR-corrected treatment success. b Plasmodium vivax treatment success. Black dotted line shows 95% and solid line 90%, which is the efficacy threshold set by the World Health Organization to replace the treatment [3]](https://figures.cochat.ai/paper-figures/4507109ece8b4b9a81dfbc2e073cc2e7/a-randomized-controlled-trial-of-dihydroartemisinin-piperaquine-artesunate-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chloroquine also proved to be a safe treatment for pregnant women infected with P. vivax [137].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early detection of Plasmodium parasites can be performed through various methods, such as TBS, RDTs, and PCR [127, 137].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMRU conducted multiple randomized controlled treatment trials and was the first study to randomize women to be treated with ACTs in the first trimester, in 2012. 17”
From Cohort Profile: the SMRU Refugee and Migrant Pregnancy Study in Western Thailand and Eastern Myanmar (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A study conducted by Saito et al. (2021) in the border region between Thailand and Myanmar found that dihydroartemisinin-piperaquine was well tolerated, safe, and showed satisfactory efficacy in pregnant women infected with P.falciparum in an area with widespread artemisinin resistance.”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as Saito et al. (2021)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Villar, J., Ismail, L. C., Victora, C. G., Ohuma, E. O., Bertino, E., Altman, D. G., Lambert, A., Papageorghiou, A. T., Carvalho, M., Jaffer, Y. A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60932-6 · Cited by 2,281
Pregnancy and Laboratory Studies: A Reference Table for Clinicians
Abbassi-Ghanavati, M., Greer, L. G., & Cunningham, F. G. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181c2bde8 · Cited by 826
Lee, A. C., Kozuki, N., Cousens, S., Stevens, G. A., Blencowe, H., Silveira, M. F., Sania, A., Rosen, H. E., Schmiegelow, C., Adair, L. S., et al. (2017) · BMJ · doi:10.1136/bmj.j3677 · Cited by 389
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Self-citationBurden, pathology, and costs of malaria in pregnancy: new developments for an old problem
Rogerson, S. J., Desai, M., Mayor, A., Sicuri, E., Taylor, S. M., & van Eijk, A. M. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30066-5 · Cited by 306
Carrara, V. I., Zwang, J., Ashley, E. A., Price, R. N., Stepniewska, K., Barends, M., Brockman, A., Anderson, T., McGready, R., Phaiphun, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004551 · Cited by 281
Self-citationvan der Pluijm, R. W., Tripura, R., Hoglund, R. M., Pyae Phyo, A., Lek, D., ul Islam, A., Anvikar, A. R., Satpathi, P., Satpathi, S., Behera, P. K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30552-3 · Cited by 271
Self-citationPhyo, A. P., Ashley, E. A., Anderson, T. J. C., Bozdech, Z., Carrara, V. I., Sriprawat, K., Nair, S., White, M. M., Dziekan, J., Ling, C., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw388 · Cited by 244
Self-citationMcGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228
Self-citationDihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy
Kakuru, A., Jagannathan, P., Muhindo, M. K., Natureeba, P., Awori, P., Nakalembe, M., Opira, B., Olwoch, P., Ategeka, J., Nayebare, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509150 · Cited by 228
Research works printed but not linked: 3
- World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO Press; 2015.
- World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO Press; 2009.
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO Press; 2011.
Cited by
Artemisinin resistance and malaria elimination: Where are we now?
Hanboonkunupakarn, B., Tärning, J., Pukrittayakamee, S., & Chotivanich, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876282 · Cited by 75
Saito, M., McGready, R. M., Tinto, H., Rouamba, T., Mosha, D., Rulisa, S., Kariuki, S., Desai, M. R., Manyando, C., Njunju, E. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01881-5 · Cited by 54
Self-citationCurrent update on malaria in pregnancy: a systematic review
Minwuyelet, A., Yewhalaw, D., Siferih, M., & Atenafu, G. (2025) · Tropical Diseases, Travel Medicine and Vaccines · doi:10.1186/s40794-025-00248-1 · Cited by 49
Artemisinins: Promising drug candidates for the treatment of autoimmune diseases
Gao, X., Lin, X., Wang, Q., & Chen, J. (2023) · Medicinal Research Reviews · doi:10.1002/med.22001 · Cited by 47
Khirikoekkong, N., Asarath, S.-A., Nosten, S., Hanboonkunupakarn, B., Jatupornpimol, N., van der Roest, J. G., Parker, M. J., Nosten, F. H., McGready, R. M., Cheah, P. Y., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001875 · Cited by 28
Self-citation
Metadata
- Authors
- Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., Phyo, A. P., Chu, C., Turner, C., Lee, S. J., Duanguppama, J., Imwong, M., Bancone, G., Proux, S., Singhasivanon, P., White, N. J., Nosten, F., & McGready, R.
- Affiliations
- Mahidol University (TH)
- University of Geneva (CH)
- Corresponding author
- McGready, Rose
- ORCID
- Venue
- BMC Medicine
- Published
- 2021-06-10
- Volume
- 19
- Issue
- 1
- Pages
- 132-132
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC8191049
- OpenAlex
- W3169799909
- Cited by
- 25
- References
- 37
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 1
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Holley Pharmacy
- Wellcome Trust (220211)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- malaria in pregnancy, dihydroartemisinin-piperaquine, artesunate-mefloquine, artemether-lumefantrine, Plasmodium falciparum, Plasmodium vivax, antimalarial drug resistance, treatment failure, cure rate, Thai-Myanmar border, Greater Mekong Subregion
- MeSH terms
- Artesunate, Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Myanmar, Drug Therapy, Combination, Female, Humans, Infant, Newborn, Malaria, Piperazines, Pregnancy, Quinolines, Thailand, Mefloquine, Malaria, Falciparum, Artemisinins, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. https://app.cochat.ai/papers/10.1186/s12916-021-02002-8
- The paper
- Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., Phyo, A. P., Chu, C., Turner, C., Lee, S. J., Duanguppama, J., Imwong, M., Bancone, G., Proux, S., Singhasivanon, P., . . . McGready, R. (2021). A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Medicine. https://doi.org/10.1186/s12916-021-02002-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.